 The European Medicines Agency EMA Committee for Orphan Medicinal Products has issued a positive opinion on Akouos Incs NASDAQ: AKUS application for orphan drug designation for AK-OTOF. AK-OTOF is a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss. 